Crossmark

Efficacy and safety of a novel cross-linked sodium hyaluronate gel for the correction of moderate-to-severe nasolabial folds: a multicenter, randomized, evaluator- and participant-blinded, active-controlled noninferiority trial

Crossref DOI link: https://doi.org/10.1186/s40001-026-04803-0

Published Online: 2026-06-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Xiecheng

Jiang, Xuan

Zhang, Jinming

Yi, Chenggang

Guo, Shu

Liu, Xinhai

Zhang, Zhiping

Cao, Meiling

Qi, Xiangdong
Funding

Funding for this research was provided by:

Shandong Jikun Bio-Pharmaceutical Co., Ltd.
License Information

Text and Data Mining valid from 2026-06-23

Version of Record valid from 2026-07-17
More Information

Article History

Received: 30 January 2026

Accepted: 18 June 2026

First Online: 23 June 2026

Declarations

Ethics approval and consent to participate: The authors declare that all procedures were performed in strict adherence to the Declaration of Helsinki, regional laws, and Good Clinical Practice (GCP) guidelines. The study protocol was prospectively filed with the Shandong Provincial Medical Products Administration (Record No. LuXieLinBei20240018; filed April 1, 2024) prior to participant enrollment. To meet international transparency standards, the trial was subsequently registered with the Chinese Clinical Trial Registry (ChiCTR2600118966; registered February 13, 2026). Written informed consent was obtained from all participants involved in the study.

Consent for publication: Written informed consent was obtained from the patient for publication of this study and any accompanying images.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below